Needham & Company Maintains a 'Buy' on Hi Tech Pharmacal (HITK); FDA Warning Letter Issues Appear in Rearview Mirror as FDA Grants Final Approval to Quixin ANDA
Tweet Send to a Friend
Needham & Company maintains a 'Buy' on Hi Tech Pharmacal (NASDAQ: HITK), PT $33.
Needham analyst says, "Quixin approval is ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "Quixin approval is ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
